SCHEMBL5590969

SCHEMBL5590969

Fc1ccc(-c2ccc(-c3nc4ccncc4[nH]3)cc2)cc1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.97
PKM P14618 2/20 0.97
KDM4E B2RXH2 5/20 0.69
HPGD P15428 3/20 0.69
NPC1 O15118 2/20 0.69
RAB9A P51151 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
AURKA O14965 1/20 0.64
HPSE Q9Y251 1/20 0.59
CYP11B1 P15538 1/20 0.55
MAPK13 O15264 2/20 0.53
GCGR P47871 2/20 0.53
MAPK12 P53778 2/20 0.53
MAPK11 Q15759 2/20 0.53
MAPK14 Q16539 2/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
FRK P42685 1/20 0.53
MAPK9 P45984 1/20 0.53
CSNK1A1 P48729 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16332640 0.98 ALDH1A1 (1.00) ALDH1A1PKMKDM4EHPGDNPC1
Hydrochloric Acid SCHEMBL7271935 0.84 ALDH1A1 (0.74) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL30104576 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL7437914 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL5591256 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL16331618 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL6245632 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL9694046 0.82 ALDH1A1 (1.00) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL21565901 0.82 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1
SCHEMBL3331253 0.81 ALDH1A1 (0.71) ALDH1A1PKMKDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007034277-A1 ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2007-03-29 WO claimed
US-10933049-B2 Mobilizing agents and uses therefor THE UNIVERSITY OF QUEENSLAND (AU) 2021-03-02 US disclosed
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2018-07-05 US disclosed
EP-3302710-A1 MOBILIZING AGENTS AND USES THEREFOR The University of Queensland (AU) 2018-04-11 EP disclosed
WO-2016191811-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2016-12-08 WO disclosed
WO-2007034277-A1 ARYL SUBSTITUTED IMIDAZO [4,5-C] PYRIDINE COMPOUNDS AS C3A RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR C3AR1, CSF3R, C5AR1 ALDH1A1 2492/4885PKM 3822/4885KDM4E 4833/4885
US-10933049-B2 Mobilizing agents and uses therefor C3AR1, CSF3R, C5AR1 ALDH1A1 2492/4885PKM 3822/4885KDM4E 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.